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Baichi: A Case of Facial Pain and Vesicular Rash
Case Presentations

A Case of Facial Pain and Vesicular Rash
Matt Baichi, MD, Resident, Internal Medicine 2000-2003

The patient is an 81 year old male with a past medical
history of non-insulin dependent diabetes mellitus,
hypertension, and dyslipidemia who presents with a
complaint of facial pain. The pain began 3-4 days before
presentation to his primary care physician. It was
constant and intense. There was no history of similar
head or facial pain, visual changes, jaw claudication, rash,
tearing, nasal discharge, photophobia, phonophobia,
sinus congestion, tooth ache, nor neurologic complaints.
There was no relief with over-the-counter analgesics. A
rash subsequently developed over his left forehead and
scalp. At presentation, vital signs were stable. Skin
examination revealed an erythematous vesicular rash over
the left forehead. Eye examination revealed pupils equal,
round, and reactive to light. Visual fields and acuity were
intact. No papilledema was noted on fundoscopic exam.
Ear, nose, mouth, and throat were normal. Neurologic
examination revealed normal mental status, intact cranial
nerves, full strength and sensation, symmetric normal
reflexes, and normal gait. Neck, heart, lung, abdomen,
and extremity examinations were normal. The patient
was diagnosed with herpes zoster. His condition was
complicated by chronic pain in the distribution of the
original rash.
Discussion
Herpes zoster (or shingles) is the reactivation of dormant
varicella virus. Herpes zoster typically presents as pain
and rash. The rash is a unilateral dermatomal eruption
that involves thoracic, cervical or ophthalmic regions. It
begins as patches of erythema and progresses to grouped
vesicles which pustulate and crust in 7-10 days. The pain
usually precedes the rash by days to weeks. The rash
usually heals in 2-4 weeks, but the pain may persist
indefinitely. Pain that persists beyond a defined interval
is termed postherpetic neuralgia (PHN).
Definition
The prevalence of PHN has been blurred by the
inconsistency in defining the condition. Some authors
define it as any pain persisting after resolution of rash.
Others define it as pain persisting for various intervals
after rash onset or resolution. A more precise classification has been proposed which includes acute and
subacute neuralgia along with postherpetic neuralgia6.

Acute herpetic neuralgia is defined as pain occurring
during the first thirty days after rash onset. Subacute
herpetic neuralgia is defined as pain that resolves within
three months after the acute phase. Postherpetic
neuralgia is defined as pain which persists beyond four
month of rash onset.
Incidence and risk factors
The incidence of PHN has been estimated by meta
analysis review of acyclovir trials in zoster associated
chronic pain7. Pooled data from the placebo arms of 14
trials (529 patients) revealed a 22% incidence of PHN
(pain at 3-6 months). It has long been known that
incidence increases with age8,9. A recent prospective
study of 421 patients with first episode herpes zoster
revealed an overall incidence of 7% at three months10. In
patients younger than 60 years, only 2% had pain at
three months, which was mild in all cases. In patients 60
years and older, both the frequency and severity of pain
increased. Overall incidence of PHN was 20% at three
months (with 1.7% being severe) and 10% at 12 months
(all with mild to moderate severity). In addition to age,
other risk factors include the severity of acute zoster pain,
the severity of the cutaneous manifestations, the severity
of sensory dysfunction in the affected dermatome, the
presence of a painful prodrome, and fever greater than
38 degrees Celsius6.
Treatment
Two recent reviews summarize the evidence supporting
the use of topical lidocaine patch, tricyclic antidepressants, gabapentin, and opioid analgesics in treating
postherpetic neuralgia2,5.
Lidocaine patch

In a double-blind controlled study, Rowbotham and
colleagues11 tested the efficacy of topical 5% lidocaine
patch in 35 patients (average age 75, average duration of
pain 48 months) with PHN of the torso or limbs.
Patients experienced significant pain relief with topical
lidocaine applied for 12 hours/day.
Antidepressants

Tricyclic antidepressants have long been the cornerstone
of PHN treatment. Max12 reviews the early evidence
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supporting their use: four placebo-controlled crossover
studies using amitriptyline (a blocker of both norepinephrine and serotonin reukptake), showed a response
rate of 44-67%; one study using desipramine (a specific
norepinephrine reuptake blocker) showed a response rate
of 63%. Side effects of these medicines include dry
mouth, urinary retention, constipation, sedation, and
orthostatic hypotension.
In a recent double-blind crossover trial comparing
nortriptyline with amitriptyline, Watson et al13 found that
both drugs had equal efficacy (55-58%) but nortriptyline
had more tolerable side effects. Inclusion criteria required
duration of PHN more than 3 months (median 13
months) with pain of at least moderate severity for at least
one half of each day. Patients were treated with 5 weeks
of one drug followed by a 2 week wash out period
followed by 5 weeks of the alternate drug. Each drug was
started at 10mg (if age greater that 65) or 20mg (if age
less than 65). Dosage was increased by 10mg every 3-5
days (max dose limit 150mg/day) until pain relief was
adequate or intolerable side effects occurred. If the latter
occurred, the dose was reduced and maintained at a
tolerable level for the remainder of the trial. The most
common side effects (in order of frequency) were dry
mouth, constipation, and drowsiness. Of the 31 patients
who completed the study, dose limiting side effects were
experienced by 5 patients using nortriptyline versus 10
patients using amitryptiline (p = 0.05). The average dose
in responders was nortriptyline 75mg per day and
amitriptyline 58mg per day.
This data supports the use of nortriptyline (dosed as
above) as first line antidepressant therapy in PHN with
amitriptyline or desipramine as alternate therapies.
Desipramine is similarly titrated by starting at 1020mg/day with an average tolerated dose of 167mg/day
with a max dose of 250mg/day (14). Max12 points out
that the benefit of this drug class can be enhanced by
future research focusing on efficacy of SSRI’s (serotonin
selective reuptake inhibitors), concentration-response
studies of the above agents, and drug combination trials.

Anticonvulsants

In 1998, Rowbotham et al15 conducted a multicenter,
randomized, double-blind, placebo-controlled, parallel
design, 8 week trial comparing gabapentin to placebo. A
total of 229 patients were randomized (gabapentin n=113,
placebo n=116). Patients in the study arm received a
starting dose of gabapentin 300mg per day. The dose was
titrated over 4 weeks to 3600mg/day divided three times
daily (regardless of whether efficacy was achieved at a lower
dose) or until intolerable side effects occurred. The dose
achieved during titration was then maintained for the
duration of the study. The primary outcome was average
daily pain as determined by a pain scale (0= no pain, 10=
worst possible pain). Over the 8 week trial, pain improved
in the gabapentin group from 6.3 to 4.2. The placebo
group went from 6.5 to 6.0. The major adverse effects in
the gabapentin group were somnolence, dizziness, ataxia,
peripheral edema, and infection. This study established
gabapentin as an additional first line agent in the treatment
of postherpetic neuralgia.
Analgesics

In 1998, Watson and Babul16 conducted a single-center,
randomized, double-blind, placebo-controlled, 8 week
crossover evaluation of oxycodone in patients with
postherpetic neuralgia. Thirty eight patients completed
the study. Each patient was randomized to receive either
oxycodone 10mg every 12 hours or placebo. The dose
was increased at weekly intervals over four weeks (10,
20, or 30mg every 12 hours) to the highest tolerated dose
(up to a maximum of 60mg/day). This was followed by
4 weeks of alternate agent with no washout period. Pain
was assessed by a daily diary using a visual analog scale
and a categorical pain intensity scale. The average
oxycodone dose at the end of 4 weeks was 45mg/day.
Patients experienced a statistically significant reduction
in pain with oxycodone compared to placebo.
Conclusion
The above evidence provides a framework for the medical
treatment of PHN. Topical lidocaine patch, tricyclic
antidepressants (especially nortriptyline), gabapentin,
and sustained release oxycodone have proven efficacy in
controlled clinical trials. A large number of alternate
agents as well as combination therapy with the above
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drugs still need to be evaluated in clinical trials. Finally,
patients should receive early referral to pain clinics where
a multidisciplinary treatment approach usually includes
cognitive-behavioral therapy which has a well established
role in other chronic pain syndromes.
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